TABLE 3

Laboratory findings for participants in the retrospective cohort study

VariablePatientsMeasurements
Mean±sdMedian (range (IQR))
GMAb mg·mL−110166.2±141.034.5 (1194.8 (59.8))
PaO2 mmHg7771.4±12.771.2 (62.5 (15.3))
PaCO2 mmHg7738.5±4.238.0 (23.4 (5.3))
PA–aO2 mmHg8029.8±15.730.1 (78.3 (22.9))
SpO2 %6095.0±3.296.0 (19 (4))
VC L703.1±0.83.2 (3.7 (1.3))
VC % predicted7494.3±19.193.9 (101.2 (19.6))
FVC cm3663.1±0.83.3 (3.6 (1.2))
FVC % predicted6493.4±19.695.8 (100.4 (20.7))
DLCO % predicted5775.8±21.475.7 (85 (36.8))
DLCO/VA % predicted5278.8±29.884.2 (140.9 (26.5))
KL-6 units·L−1794915±53853181 (31 143 (5407))
LDH international units·L−178315.3±156.3254.5 (771 (158.5))

IQR: interquartile range; GMAb: granulocyte-macrophage colony-stimulating factor autoantibody; PaO2: arterial oxygen tension; PaCO2: arterial carbon dioxide tension; PA–aO2: alveolar–arterial oxygen tension difference (alveolar–arterial oxygen gradient); SpO2: arterial oxygen saturation measured by pulse oximetry; VC: vital capacity; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; VA: alveolar volume; KL-6: mucin-like glycoprotein; LDH: lactate dehydrogenase.